Skip to main content

Table 1 Baseline characteristics in RA patients who were receiving MTX and comparison between patients with and without abnormal liver stiffness measurement (LSM)

From: Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate

  All patients (n= 105) LSM < 5.3 kPa(n= 81) LSM > 5.3 kPa(n= 24) P-value
Demographic variables     
Age, years 54.0 (25, 73) 52.5 ± 10.3 52.3 ± 11.8 0.852
Male gender 20 (19.0) 16 (19.8) 4 (16.7) 0.736
Body mass index, kg/m2 22.1 (18.1, 27.6) 22.1 ± 2.5 22.3 ± 2.4 0.723
Metabolic syndrome, number patients (%) 6 (5.7) 3 (3.7) 3 (12.5) 0.105
Disease duration, weeks 140.4 (26.1, 739.2) 171.8 ± 123.9 240.5 ± 159 0.059
Laboratory variables     
C-reactive protein, mg/L 1.2 (0, 124.0) 3.1 ± 5.7 6.9 ± 25.1 0.766
Erythrocyte sedimentation rate, mm/hr 33.0 (2, 111) 37.3 ± 22.3 32.4 ± 20.7 0.362
White blood cells, count/mm3 5,960.0 (2,390.0, 12,870.0) 6,355.9 ± 2,009.0 5,801.7 ± 1,853.9 0.319
Hemoglobin, g/dL 12.7 (9.9, 16.2) 12.7 ± 1.1 13.0 ± 1.0 0.324
Platelet count, × 1,000/mm3 241.0 (134.0, 470.0) 253.0 ± 60.3 250.8 ± 69.0 0.723
Prothrombin time, INR 0.9 (0.8, 1.2) 1.0 ± 0.1 1.0 ± 0.1 0.726
Glucose, mg/dL 85.0 (70.0, 125.0) 87.4 ± 10.7 86.4 ± 5.0 0.652
Blood urea nitrogen, mg/dL 14.4 (0.9, 28.1) 15.2 ± 4.8 14.1 ± 4.6 0.249
Creatinine mg/dL 0.7 (0.5, 1.3) 0.7 ± 0.2 0.7 ± 0.1 0.858
Uric acid, mg/dL 3.8 (1.5, 8.9) 4.0 ± 1.2 4.1 ± 1.8 0.582
Aspartate aminotransferase, IU/L 21.0 (13.0, 34.0) 21.9 ± 5.5 22.4 ± 6.8 0.881
Alanine aminotransferase, IU/L 17.0 (8.0, 39.0) 18.9 ± 7.7 19.0 ± 7.7 0.879
Total protein, mg/dL 6.9 (5.5, 7.9) 7.0 ± 0.4 7.0 ± 0.5 0.730
Serum albumin, mg/dL 4.3 (3.5, 4.9) 4.3 ± 0.3 4.2 ± 0.4 0.815
Total bilirubin, mg/dL 0.6 (0.2, 1.1) 0.6 ± 0.2 0.6 ± 0.2 0.461
Alkaline phosphatase, IU/L 52.0 (38.0, 110.0) 56.4 ± 17.0 54.7 ± 13.1 0.976
Gamma-glutamyltranspeptidase, IU/L 17.0 (5.0, 53.0) 22.6 ± 15.1 26.3 ± 19.1 0.340
Triglyceride, mg/dL 90.0 (26.0, 269.0) 108.9 ± 55.4 92.2 ± 41.4 0.197
High density cholesterol, mg/dL 55.0 (19.0, 86.0) 55.9 ± 10.4 53.2 ± 19.1 0.772
Low density cholesterol, mg/dL 105.4 (52.8, 172.6) 108.8 ± 26.8 107.4 ± 26.8 0.743
Cumulative dose of medication, mg     
Methotrexate (105 patients) 2,032.5 (285.0, 7,800.0) 2,334.0 ± 1,939.9 3,127.9 ± 2,072.7 0.086
Leflunomide (53 patients) 7,800.0 (280.0, 38,520.0) 9,291.1 ± 9,331.8 19,919.3 ± 12,716.8 0.008
Sulfasalazine (82 patients) 360,000.0 (30,000.0, 6,028,000.0) 727,778.7 ± 969,150.7 1,093,547.6 ± 1,330,930.2 0.111
Hydroxychloroquine (65 patients) 94,600.0 (4,200.0, 868,000.0) 115,248.0 ± 120,975.1 182,013.3 ± 208,807.9 0.129
Prednisolone (89 patients) 3,015.0 (372.5, 20,212.5) 4,642.1.0 ± 4,196.7 6,756.7.1 ± 6,156.5 0.472
Meloxicam (90 patients) 6,273.8 (210.0, 2,895,000.0) 90,205.0 ± 363,930.2 161,274.6 ± 644,791.4 0.793
Celecoxib (70 patients) 163,000.0 (1,000.0, 1,503,000.0) 218,505.7 ± 253,487.6 316,705.9 ± 313,982.7 0.239
LSM     
LSM, kPa, median (range) 4.4 (2.8, 17.8) NA NA NA
LSM, kPa, median (IQR) 0.14 (0.02, 0.29) NA NA NA
Success rate, %, median (IQR) 100.0 (63.0, 100.0) NA NA NA
  1. Values are expressed as median (range, IQR), number (%), or mean ± SD. INR, international normalized ratio; NA: not applicable.